Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.42 |
| ▸ | ROR1 | Q01973 | 2/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15443081 | 0.83 | ABL1 (0.51) | ABL1DDR1CSF1RROR1 | |
| SCHEMBL25649582 | 0.78 | ABL1 (0.56) | ABL1DDR1CSF1RROR1GAK | |
| SCHEMBL15443267 | 0.78 | ABL1 (0.51) | ABL1DDR1CSF1RROR1 | |
| SCHEMBL15443243 | 0.75 | ABL1 (0.58) | ABL1DDR1CSF1RGAKMLNR | |
| SCHEMBL16644465 | 0.69 | ABL1 (1.00) | ABL1DDR1CSF1RROR1GAK | |
| SCHEMBL4469809 | 0.69 | KDM4E (0.64) | KCNH2 | |
| Trifluoroacetic Acid SCHEMBL30879813 | 0.68 | ABL1 (0.58) | ABL1DDR1CSF1RROR1GAK | |
| SCHEMBL30458494 | 0.67 | CSF1R (0.52) | ABL1CSF1RROR1 | |
| SCHEMBL22580709 | 0.67 | CSF1R (0.61) | ABL1CSF1RROR1CYP3A4FGFR1 | |
| SCHEMBL15096062 | 0.67 | ROR1 (0.67) | ABL1DDR1CSF1RROR1GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | ABL1 75/4885DDR1 2431/4885CSF1R 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.